Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%

By CNBC
| August 08, 2023

The results of the closely watched 'SELECT' trial, which exceeded analyst expectations, were seen as a major boost for the firm's hopes of moving beyond Wegovy's image as a 'vanity drug.'

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...